 |
We are advised by Antengene Corporation Limited that journalists and other readers should disregard the news release, Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug, issued 28-Jul-2025 over PR Newswire.
source: Antengene Corporation Limited
【你點睇？】超颱「樺加沙」襲港期間，柴灣有母子因觀浪墮海命危。你認為應否進一步立法禁惡劣天氣下所有岸邊觀浪行為？► 立即投票
